2023 Vol.41, N°2 - Table of contents
February - Myositis 2023
Official organ of the International Myositis Society
(iMyoS - https://imyos.org/)
One year in review
CER16499
2023,41,2
Pg. 0199-0213
Free to view
Idiopathic inflammatory myopathies: one year in review 2022
E. Dourado, F. Bottazzi, C. Cardelli, E. Conticini, J. Schmidt, L. Cavagna, S. Barsotti
DOI: https://doi.org/10.55563/clinexprheumatol/jof6qn
E. Dourado, F. Bottazzi, C. Cardelli, E. Conticini, J. Schmidt, L. Cavagna, S. Barsotti
DOI: https://doi.org/10.55563/clinexprheumatol/jof6qn
Editorials
CER16321
2023,41,2
Pg. 0214-0216
Free to view
Working towards a patient-centred Global Myositis Alliance: call for partnership
S. Schlüter, I. De Groot, M. Lubinus, A. Dihkan, J. Johnsson, O. Drápalová, I. Oakley
DOI: https://doi.org/10.55563/clinexprheumatol/u1pdqm
S. Schlüter, I. De Groot, M. Lubinus, A. Dihkan, J. Johnsson, O. Drápalová, I. Oakley
DOI: https://doi.org/10.55563/clinexprheumatol/u1pdqm
CER16584
2023,41,2
Pg. 0217-0220
Free to view
Idiopathic inflammatory myopathies and COVID-19: an intriguing liaison?
L. Cavagna, F. Ferro, G. Zanframundo, G. La Rocca, I. Puxeddu
DOI: https://doi.org/10.55563/clinexprheumatol/njaff0
L. Cavagna, F. Ferro, G. Zanframundo, G. La Rocca, I. Puxeddu
DOI: https://doi.org/10.55563/clinexprheumatol/njaff0
Full Papers
CER15364
2023,41,2
Pg. 0221-0229
Free to view
Transcranial direct current stimulation is safe and effective in autoimmune myopathies: a randomised, double-blind, sham-controlled trial
L.F. De Sousa, R.G. Missé, L.M. Dos Santos, C. Tanaka, J.M. Greve, A.F. Baptista, S.K. Shinjo
DOI: https://doi.org/10.55563/clinexprheumatol/qjm9hb
L.F. De Sousa, R.G. Missé, L.M. Dos Santos, C. Tanaka, J.M. Greve, A.F. Baptista, S.K. Shinjo
DOI: https://doi.org/10.55563/clinexprheumatol/qjm9hb
CER15562
2023,41,2
Pg. 0230-0237
Free to view
Association of the serum IgG glycosylation with disease activity of anti-transcription intermediary factor 1 gamma positive dermatomyositis
X. Li, J. Bai, S. Li, M. Li, X. Zeng, Q. Wang, C. Hu
DOI: https://doi.org/10.55563/clinexprheumatol/pdrum6
X. Li, J. Bai, S. Li, M. Li, X. Zeng, Q. Wang, C. Hu
DOI: https://doi.org/10.55563/clinexprheumatol/pdrum6
CER15463
2023,41,2
Pg. 0238-0246
Free to view
High prevalence of necrotising myopathy pattern in muscle biopsies of patients with anti-Jo-1 antisynthetase syndrome
L.M. Da Silva, I.B. Borges, S.K. Shinjo
DOI: https://doi.org/10.55563/clinexprheumatol/zq7x68
L.M. Da Silva, I.B. Borges, S.K. Shinjo
DOI: https://doi.org/10.55563/clinexprheumatol/zq7x68
CER15604
2023,41,2
Pg. 0247-0253
Free to view
Interstitial lung disease in adult patients with anti-NXP2 antibody positivity: a multicentre 18-month follow-up study
T. Yan, Y. Du, W. Sun, X. Chen, Q. Wu, Q. Ye, S. Chen, J. Xue
DOI: https://doi.org/10.55563/clinexprheumatol/lqjx4h
T. Yan, Y. Du, W. Sun, X. Chen, Q. Wu, Q. Ye, S. Chen, J. Xue
DOI: https://doi.org/10.55563/clinexprheumatol/lqjx4h
CER15577
2023,41,2
Pg. 0254-0260
Free to view
The effect of COVID-19 pandemic on idiopathic inflammatory myositis patients: a single centre experience
T. Béldi, A. Vincze, B. Miltényi-Szabó, Z. Varga, K. Szabó, Z. Griger, M. Nagy-Vincze
DOI: https://doi.org/10.55563/clinexprheumatol/eisexh
T. Béldi, A. Vincze, B. Miltényi-Szabó, Z. Varga, K. Szabó, Z. Griger, M. Nagy-Vincze
DOI: https://doi.org/10.55563/clinexprheumatol/eisexh
CER15886
2023,41,2
Pg. 0261-0266
Free to view
In-patient comorbidities in inclusion body myositis: a United States national in-patient sample-based study
A.K. Ma, F. Dai, B. Roy
DOI: https://doi.org/10.55563/clinexprheumatol/791fq8
A.K. Ma, F. Dai, B. Roy
DOI: https://doi.org/10.55563/clinexprheumatol/791fq8
CER15908
2023,41,2
Pg. 0267-0274
Free to view
Increased serum levels of sCD40L were associated with rapidly progressive interstitial lung disease in idiopathic inflammatory myopathies
W. Lyu, W. Zhou, Q. Xu, X. Liu, Y. Liu, Y. Zhang, Y. Qiu, M. Huang, M. Cao, Y. Xiao, H. Cai, J. Dai
DOI: https://doi.org/10.55563/clinexprheumatol/a4a9ln
W. Lyu, W. Zhou, Q. Xu, X. Liu, Y. Liu, Y. Zhang, Y. Qiu, M. Huang, M. Cao, Y. Xiao, H. Cai, J. Dai
DOI: https://doi.org/10.55563/clinexprheumatol/a4a9ln
CER16192
2023,41,2
Pg. 0275-0284
Free to view
Potential role of type I interferon/IP-10 axis in the pathogenesis of anti-MDA5 antibody-positive dermatomyositis
A. Kokuzawa, J. Nakamura, Y. Kamata, K. Sato
DOI: https://doi.org/10.55563/clinexprheumatol/em67zx
A. Kokuzawa, J. Nakamura, Y. Kamata, K. Sato
DOI: https://doi.org/10.55563/clinexprheumatol/em67zx
CER16244
2023,41,2
Pg. 0285-0290
Free to view
Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study
E. Conticini, M. D'alessandro, S. Grazzini, C. Rizzo, M. Fornaro, P. Cameli, D. Bennett, A. Abbruzzese, F. Camarda, G. Lopalco, L. Bergantini, P. Falsetti, E. Bargagli, F. Iannone, G. Guggino, H. Chinoy, L. Cantarini, B. Frediani
DOI: https://doi.org/10.55563/clinexprheumatol/790ihy
E. Conticini, M. D'alessandro, S. Grazzini, C. Rizzo, M. Fornaro, P. Cameli, D. Bennett, A. Abbruzzese, F. Camarda, G. Lopalco, L. Bergantini, P. Falsetti, E. Bargagli, F. Iannone, G. Guggino, H. Chinoy, L. Cantarini, B. Frediani
DOI: https://doi.org/10.55563/clinexprheumatol/790ihy
CER16301
2023,41,2
Pg. 0291-0300
Free to view
Intensive induction therapy combining tofacitinib, rituximab and plasma exchange in severe anti-melanoma differentiation-associated
protein-5 antibody-positive dermatomyositis
T. Shirai, T. Machiyama, H. Sato, T. Ishii, H. Fujii
DOI: https://doi.org/10.55563/clinexprheumatol/8kulbf
T. Shirai, T. Machiyama, H. Sato, T. Ishii, H. Fujii
DOI: https://doi.org/10.55563/clinexprheumatol/8kulbf
CER16102
2023,41,2
Pg. 0301-0308
Free to view
The role of magnetic resonance imaging in the diagnostic work-out of myopathies: differential diagnosis between inflammatory myopathies and muscular dystrophies
S. Barsotti, G. Aringhieri, B. Mugellini, F. Torri, F. Minichilli, A. Tripoli, C. Cardelli, E. Cioffi, V. Zampa, G. Siciliano, D. Caramella, G. Ricci, M. Mosca
DOI: https://doi.org/10.55563/clinexprheumatol/dkmz6o
S. Barsotti, G. Aringhieri, B. Mugellini, F. Torri, F. Minichilli, A. Tripoli, C. Cardelli, E. Cioffi, V. Zampa, G. Siciliano, D. Caramella, G. Ricci, M. Mosca
DOI: https://doi.org/10.55563/clinexprheumatol/dkmz6o
CER16289
2023,41,2
Pg. 0309-0315
Free to view
Anti-MDA5-positive dermatomyositis and remission in a single referral centre population
E. Tiniakou, C.A. Mecoli, W. Kelly, J. Albayda, J.J. Paik, B.L. Adler, C.T. Lin, A.L. Mammen, S.K. Danoff, L. Casciola-Rosen, L. Christopher-Stine
DOI: https://doi.org/10.55563/clinexprheumatol/g4l70r
E. Tiniakou, C.A. Mecoli, W. Kelly, J. Albayda, J.J. Paik, B.L. Adler, C.T. Lin, A.L. Mammen, S.K. Danoff, L. Casciola-Rosen, L. Christopher-Stine
DOI: https://doi.org/10.55563/clinexprheumatol/g4l70r
CER16518
2023,41,2
Pg. 0316-0321
Free to view
Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience
F. Kharouf, A. Kenig, E. Bohbot, L. Rubin, H. Peleg, O. Shamriz
DOI: https://doi.org/10.55563/clinexprheumatol/970881
F. Kharouf, A. Kenig, E. Bohbot, L. Rubin, H. Peleg, O. Shamriz
DOI: https://doi.org/10.55563/clinexprheumatol/970881
CER16533
2023,41,2
Pg. 0322-0329
Free to view
Long-term survival of patients with idiopathic inflammatory myopathies: anatomy of a single-centre cohort
F. Guimarães, R. Yildirim, D.A. Isenberg
DOI: https://doi.org/10.55563/clinexprheumatol/486yh4
F. Guimarães, R. Yildirim, D.A. Isenberg
DOI: https://doi.org/10.55563/clinexprheumatol/486yh4
CER16544
2023,41,2
Pg. 0330-0339
Free to view
Application of logistic regression and machine learning methods for idiopathic inflammatory myopathies malignancy prediction
W. Zhang, G. Huang, K. Zheng, J. Lin, S. Hu, S. Zheng, G. Du, G. Zhang, C. Bruni, M. Matucci-Cerinic, D.E. Furst, Y. Wang
DOI: https://doi.org/10.55563/clinexprheumatol/8ievtq
W. Zhang, G. Huang, K. Zheng, J. Lin, S. Hu, S. Zheng, G. Du, G. Zhang, C. Bruni, M. Matucci-Cerinic, D.E. Furst, Y. Wang
DOI: https://doi.org/10.55563/clinexprheumatol/8ievtq
CER16540
2023,41,2
Pg. 0340-0347
Free to view
Two emerging phenotypes of atypical inclusion body myositis: illustrative cases
S. Salam, J.M. Morrow, R. Howard, J.A. Miller, R.M. Quinlivan, P.M. Machado
DOI: https://doi.org/10.55563/clinexprheumatol/jq7zxd
S. Salam, J.M. Morrow, R. Howard, J.A. Miller, R.M. Quinlivan, P.M. Machado
DOI: https://doi.org/10.55563/clinexprheumatol/jq7zxd
Reviews
CER15596
2023,41,2
Pg. 0348-0358
Free to view
Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review
J.J. Paik, G. Lubin, A. Gromatzky, P.N. Mudd, Jr., M.P. Ponda, L. Christopher-Stine
DOI: https://doi.org/10.55563/clinexprheumatol/hxin6o
J.J. Paik, G. Lubin, A. Gromatzky, P.N. Mudd, Jr., M.P. Ponda, L. Christopher-Stine
DOI: https://doi.org/10.55563/clinexprheumatol/hxin6o
CER16382
2023,41,2
Pg. 0359-0369
Free to view
Current concepts and advances in dermatomyositis: a dermatological perspective
D. Lim, D. Fiorentino, V. Werth
DOI: https://doi.org/10.55563/clinexprheumatol/ue71ku
D. Lim, D. Fiorentino, V. Werth
DOI: https://doi.org/10.55563/clinexprheumatol/ue71ku
CER16059
2023,41,2
Pg. 0370-0378
Free to view
Current status of clinical outcome measures in inclusion body myositis: a systematised review
B. Roy, M. Lucchini, J.B. Lilleker, N.A. Goyal, E. Naddaf, B. Adler, L.N. Alfano, G.A. Malandraki, K.L. (focht) Garand, D. Mochel, U. Badrising, P.M. Machado, R. Pagkatipunan, G. Ramdharry, L. Wang, M.C. Funaro, J. Schmidt, H. Kushlaf, E. Schiopu, K. Stipancic, N. Goyal, M. D'alessandro, E. Conticini, B. Cruz-Coble, T.E. Lloyd
for the International Myositis Assessment and Clinical Studies (IMACS) Inclusion Body Myositis Scientific Interest Group
DOI: https://doi.org/10.55563/clinexprheumatol/ifacv3
B. Roy, M. Lucchini, J.B. Lilleker, N.A. Goyal, E. Naddaf, B. Adler, L.N. Alfano, G.A. Malandraki, K.L. (focht) Garand, D. Mochel, U. Badrising, P.M. Machado, R. Pagkatipunan, G. Ramdharry, L. Wang, M.C. Funaro, J. Schmidt, H. Kushlaf, E. Schiopu, K. Stipancic, N. Goyal, M. D'alessandro, E. Conticini, B. Cruz-Coble, T.E. Lloyd
for the International Myositis Assessment and Clinical Studies (IMACS) Inclusion Body Myositis Scientific Interest Group
DOI: https://doi.org/10.55563/clinexprheumatol/ifacv3
CER16418
2023,41,2
Pg. 0379-0385
Free to view
Immune checkpoint inhibitor-related myositis: from pathophysiology to treatment
C. Sundarrajan, S. Bhai, M.M. Dimachkie
DOI: https://doi.org/10.55563/clinexprheumatol/q7mdjs
C. Sundarrajan, S. Bhai, M.M. Dimachkie
DOI: https://doi.org/10.55563/clinexprheumatol/q7mdjs
CER16349
2023,41,2
Pg. 0386-0392
Free to view
Imaging beyond muscle magnetic resonance imaging in inclusion body myositis
N.A. Goyal, T. Mozaffar, M.M. Dimachkie
DOI: https://doi.org/10.55563/clinexprheumatol/uimkey
N.A. Goyal, T. Mozaffar, M.M. Dimachkie
DOI: https://doi.org/10.55563/clinexprheumatol/uimkey
Letters to the Editor
CER15404
2023,41,2
Pg. 0393
Free to view
Serum levels of lysyl oxidase-like 2 are increased in patients with dermatomyositis
M. Yang, Y. Chen, S. Lin, H. Liu, Q. Xie
DOI: https://doi.org/10.55563/clinexprheumatol/jikxzi
M. Yang, Y. Chen, S. Lin, H. Liu, Q. Xie
DOI: https://doi.org/10.55563/clinexprheumatol/jikxzi
CER15771
2023,41,2
Pg. 0394
Free to view
Different clinical phenotypes in anti-melanoma differentiation-associated protein 5-associated positive dermatomyositis
P.A. Olivo Pallo, S.K. Shinjo
DOI: https://doi.org/10.55563/clinexprheumatol/8qzeg2
P.A. Olivo Pallo, S.K. Shinjo
DOI: https://doi.org/10.55563/clinexprheumatol/8qzeg2
CER16063
2023,41,2
Pg. 0395
Free to view
Anti-TIF1-γ antibody-positive dermatomyositis caused by camrelizumab in a patient with oesophageal cancer
J. Li, S. Yi, Y. Huang, Y. Peng, Z. Yang
DOI: https://doi.org/10.55563/clinexprheumatol/knb47b
J. Li, S. Yi, Y. Huang, Y. Peng, Z. Yang
DOI: https://doi.org/10.55563/clinexprheumatol/knb47b
CER16206
2023,41,2
Pg. 0396-0397
Free to view
Efficacy and safety of apremilast in a patient with paraneoplastic dermatomyositis with resistant skin disease
N. Cabas, M. Turina, S. Pizzolitto, S. De Vita, L. Quartuccio
DOI: https://doi.org/10.55563/clinexprheumatol/e3gjax
N. Cabas, M. Turina, S. Pizzolitto, S. De Vita, L. Quartuccio
DOI: https://doi.org/10.55563/clinexprheumatol/e3gjax
CER16235
2023,41,2
Pg. 0398
Free to view
Juvenile dermatomyositis in a Duchenne muscular dystrophy carrier
S. Hao, D. Yue, W. Zhu, W. Huang
DOI: https://doi.org/10.55563/clinexprheumatol/y3jx9l
S. Hao, D. Yue, W. Zhu, W. Huang
DOI: https://doi.org/10.55563/clinexprheumatol/y3jx9l
CER16503
2023,41,2
Pg. 0399
Free to view
Paucity of bulbar function measures in inclusion body myositis trials. Reply to: Current status of clinical outcome measures in inclusion body myositis: a systematised review
K.L. (focht) Garand, G.A. Malandraki, K.L. Stipancic, E. Kearney, B. Roy, L.N. Alfano
DOI: https://doi.org/10.55563/clinexprheumatol/x66elf
K.L. (focht) Garand, G.A. Malandraki, K.L. Stipancic, E. Kearney, B. Roy, L.N. Alfano
DOI: https://doi.org/10.55563/clinexprheumatol/x66elf
CER16402
2023,41,2
Pg. 0400-0401
Free to view
Anti-EJ antibody-positive antisynthetase syndrome developed pulmonary arterial hypertension 7 years after the onset of disease: the necessity of periodic evaluation
K. Aso, H. Kasahara
DOI: https://doi.org/10.55563/clinexprheumatol/eg7mxg
K. Aso, H. Kasahara
DOI: https://doi.org/10.55563/clinexprheumatol/eg7mxg
CER16468
2023,41,2
Pg. 0402-0403
Free to view
Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis
M.V. Mastrolia, S.I. Orsini, E. Marrani, I. Maccora, I. Pagnini, G. Simonini
DOI: https://doi.org/10.55563/clinexprheumatol/7k9ajj
M.V. Mastrolia, S.I. Orsini, E. Marrani, I. Maccora, I. Pagnini, G. Simonini
DOI: https://doi.org/10.55563/clinexprheumatol/7k9ajj
Meeting Abstracts
CER16388
2023,41,2
Pg. 0405-0542
Free to view
4th Global Conference on Myositis (GCOM)
J. Vencovský, M. Klein, H. Mann, K. Kubínová, O. Kryštůfková, H. Šmucrová
6-9 June 2022, Prague, Czech Republic
DOI: https://doi.org/10.55563/clinexprheumatol/zka1xq
J. Vencovský, M. Klein, H. Mann, K. Kubínová, O. Kryštůfková, H. Šmucrová
6-9 June 2022, Prague, Czech Republic
DOI: https://doi.org/10.55563/clinexprheumatol/zka1xq